AIRA Matrix and Gestalt have forged a strategic partnership to integrate AIRA Matrix’s AI-powered quality control solution, AIRAQC, into Gestalt’s PathFlow platform. Announced on March 24, 2025, this collaboration aims to boost diagnostic precision and efficiency in labs globally.
AIRAQC uses artificial intelligence to streamline quality control, enabling quicker and more precise analysis in pathology. Its integration with Gestalt’s system offers pathologists a smooth, AI-enhanced experience that optimizes diagnostic decisions.
“We’re thrilled to partner with Gestalt to expand the reach of AIRAQC and deliver transformative AI capabilities to pathology labs,” said Marco Comianos, Head of Commercial Operations – US., AIRA Matrix.
Relativity’s aiR now supercharges government document review
Lisa-Jean Clifford, Gestalt COO & Chief Strategy Officer, states that the partnership signifies an effort to advance pathology, meeting evolving healthcare needs by providing labs with tools improving diagnostic accuracy, quality and meaningful metrics at the start of the diagnostic process.
AIRA Matrix specializes in AI solutions for healthcare and life sciences, offering products that enhance diagnostic accuracy and provide data-driven insights from digital images. Their AI suite aids drug discovery and development by streamlining pre-analytical quality control, tissue triage, and safety assessments.
Gestalt focuses on transforming pathology through an intelligent, configurable, and AI-driven digital workflow, PathFlow. This solution offers interoperability, allowing pathologists to diagnose diseases faster and more efficiently by reducing manual tasks.
